Literature DB >> 25015163

Acute hepatitis after starting pinaverium bromide in a patient taking mirtazapine.

Sandeep Tak1, Shubhanjali Tak2.   

Abstract

A 56-year-old man presented with chronic abdominal pain. He had been evaluated extensively in the recent past undergoing upper gastrointestinal endoscopy, colonoscopy and CT scan of the abdomen with normal results. The provisional diagnosis of irritable bowel syndrome was performed and pinaverium bromide was started. The patient had pre-existing hypertension, a major depressive disorder and gastro-oesophageal reflux disease. He had been taking nebivolol and pantoprazole for several years and mirtazapine for the last 1 year. The patient developed nausea, vomiting and anorexia after 5 days of starting pinaverium bromide. Investigations revealed marked elevation of liver enzymes and bilirubin. He was negative for HIV, HBSAg, anti-hepatitis C virus, IgM for hepatitis A virus, hepatitis E virus, antinuclear antibody and antimitochondrial antibody. An ultrasound showed mild hepatomegaly with hypoechoic echo texture; the rest of scan was normal. Pinaverium and mirtazapine were stopped immediately. The patient was treated symptomatically and his liver profile returned to normal after 4 weeks. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25015163      PMCID: PMC4112329          DOI: 10.1136/bcr-2013-200947

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  25 in total

Review 1.  Apoptosis-regulating proteins as targets for drug discovery.

Authors:  J C Reed
Journal:  Trends Mol Med       Date:  2001-07       Impact factor: 11.951

Review 2.  Safety of mirtazapine: a review.

Authors:  S A Montgomery
Journal:  Int Clin Psychopharmacol       Date:  1995-12       Impact factor: 1.659

3.  Mirtazapine-associated dose-dependent and asymptomatic elevation of hepatic enzymes.

Authors:  Babatunde Adetunji; Biju Basil; Maju Mathews; Thomas Osinowo
Journal:  Ann Pharmacother       Date:  2007-01-23       Impact factor: 3.154

Review 4.  Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis.

Authors:  M A Robin; M Le Roy; V Descatoire; D Pessayre
Journal:  J Hepatol       Date:  1997       Impact factor: 25.083

Review 5.  Mitochondria in steatohepatitis.

Authors:  D Pessayre; A Berson; B Fromenty; A Mansouri
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

Review 6.  Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disorders.

Authors:  M O Christen
Journal:  Gen Pharmacol       Date:  1990

Review 7.  Clinical pharmacokinetics of mirtazapine.

Authors:  C J Timmer; J M Sitsen; L P Delbressine
Journal:  Clin Pharmacokinet       Date:  2000-06       Impact factor: 6.447

Review 8.  Multicultural considerations in the diagnosis and management of irritable bowel syndrome: a selective summary.

Authors:  Sarah K Ballou; Laurie Keefer
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-10       Impact factor: 2.566

9.  Drug-induced liver injury.

Authors:  Neil Kaplowitz
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

10.  Prevalence of depression and anxiety in irritable bowel syndrome: A clinic based study from India.

Authors:  Neeraj Kabra; Abhijit Nadkarni
Journal:  Indian J Psychiatry       Date:  2013-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.